This document is a published patent application (US20260085294A1) from the USPTO concerning a novel process for producing purified rhabdoviruses from cell cultures. The invention focuses on oncolytic rhabdoviruses, particularly vesicular stomatitis virus, and includes methods for upstream and downstream processing, as well as pharmaceutical compositions containing the virus. The application was filed on August 21, 2025, and published on March 26, 2026.

While patent applications do not impose direct regulatory obligations on entities, this publication signals potential future developments in the biotechnology and pharmaceutical sectors. Companies involved in viral vector development, gene therapy, or oncolytic virus research should review this application to understand emerging technologies and potential intellectual property landscapes. No immediate compliance actions are required, but awareness of this patented process may inform R&D strategies and competitive analysis.